Health-related quality of life (HRQOL) is not negatively impacted by therapy of MK-5172/MK-8742 during treatment of genotype (GT) 1 chronic hepatitis C in contrast to pegylated-interferon (IFN) or ribavirin (RBV)-containing therapy

被引：0
|
作者：
Arduino, Jean Marie [1 ]
Zhang, Boan [1 ]
Nwankwo, Chizoba [1 ]
Khawaja, Shazia [1 ]
Shaughnessy, Melissa [1 ]
Gendrano, Isaias N. [1 ]
Hwang, Peggy [1 ]
Robertson, Michael [1 ]
Mobashery, Niloufar [1 ]
Haber, Barbara A. [1 ]
机构：
[1] Merck & Co Inc, Whitehouse Stn, NJ USA
来源：
HEPATOLOGY | 2014年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1455
引用
收藏
页码：897A / 898A
页数：2
相关论文
共 31 条
  • [1] C-SALVAGE: GRAZOPREVIR (GZR; MK-5172), ELBASVIR (EBR; MK-8742) AND RIBAVIRIN (RBV) FOR CHRONIC HCV-GENOTYPE 1 (GT1) INFECTION AFTER FAILURE OF DIRECT-ACTING ANTIVIRAL (DAA) THERAPY
    Forns, X.
    Gordon, S.
    Zuckerman, E.
    Lawitz, E.
    Buti, M.
    Calleja Panero, J.
    Hofer, H.
    Gilbert, C.
    Palcza, J.
    Howe, A.
    DiNubile, M.
    Robertson, M.
    Wahl, J.
    Barr, E.
    Sullivan-Bolyai, J.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S190 - S190
  • [2] Health-related quality of life in Greek chronic hepatitis C patients during pegylated interferon and ribavirin treatment
    Sinakos, E.
    Gigi, E.
    Lalla, T.
    Bellou, A-L
    Sykja, A.
    Orphanou, E.
    Vrettou, E.
    Tsapas, V
    Raptopoulou, M.
    HIPPOKRATIA, 2010, 14 (02) : 122 - 125
  • [3] Projected Long-Term Impact of Grazoprevir (GZR, MK-5172)/ Elbasvir (EBR, MK-8742) in Treatment-Naive and Treatment-Experienced Patients with Hepatitis C Virus Genotype 1 Infection and Chronic Kidney Disease
    Ferrante, Shannon A.
    Elbasha, Elamin
    Greaves, Wayne
    Nwankwo, Chizoba
    HEPATOLOGY, 2015, 62 : 571A - 572A
  • [4] Assessment of health-related quality of life and how it predicts the outcome of pegylated interferon and ribavirin therapy for chronic hepatitis C
    Matsushita, Hiroshi
    Ikeda, Fusao
    Iwasaki, Yoshiaki
    Seki, Hiroyuki
    Nanba, Shintaro
    Takeuchi, Yasuto
    Moritou, Yuki
    Yasunaka, Tetsuya
    Onishi, Hideki
    Miyake, Yasuhiro
    Takaki, Akinobu
    Nouso, Kazuhiro
    Yamamoto, Kazuhide
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2014, 29 (02) : 337 - 343
  • [5] Virologic Resistance Analysis From a Phase 2 Study of MK-5172 Combined With Pegylated Interferon/Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection
    Howe, Anita Y. M.
    Black, Stuart
    Curry, Stephanie
    Ludmerer, Steven W.
    Liu, Rong
    Barnard, Richard J. O.
    Newhard, William
    Hwang, Peggy M. T.
    Nickle, David
    Gilbert, Christopher
    Caro, Luzelena
    DiNubile, Mark J.
    Mobashery, Niloufar
    CLINICAL INFECTIOUS DISEASES, 2014, 59 (12) : 1657 - 1665
  • [6] Dynamic Changes of Health-Related Quality of Life After Pegylated Interferon and Ribavirin Treatment for Chronic Hepatitis C
    Chang, Chi-Yang
    Mo, Lein-Ray
    Tseng, Chen-Haug
    Hsu, Yao-Chun
    Lin, Jaw-Town
    GASTROENTEROLOGY, 2013, 144 (05) : S981 - S981
  • [7] COST-EFFECTIVENESS OF ELBASVIR (EBR, MK-8742)/GRAZOPREVIR (GZR, MK-5172) USE IN TREATMENT-NAIVE AND TREATMENT-EXPERIENCED PATIENTS WITH HEPATITIS C VIRUS (HCV) GENOTYPE 1 INFECTION AND CHRONIC KIDNEY DISEASE (CKD) IN THE UNITED STATES
    Elbasha, E.
    Greaves, W.
    Nwankwo, C.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S760 - S760
  • [8] THE PHASE 3 C-EDGE TREATMENT-NAIVE (TN) STUDY OF A 12-WEEK ORAL REGIMEN OF GRAZOPREVIR (GZR, MK-5172)/ELBASVIR (EBR, MK-8742) IN PATIENTS WITH CHRONIC HCV GENOTYPE (GT) 1, 4, OR 6 INFECTION
    Zeuzem, S.
    Ghalib, R.
    Reddy, K. R.
    Pockros, P. J.
    Ari, Z. B.
    Zhao, Y.
    Brown, D.
    DiNubile, M.
    Robertson, M.
    Wahl, J.
    Barr, E.
    Butterton, J.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S213 - S213
  • [9] Health-related quality of life (HRQOL) with albinterferon alfa-213 plus ribavirin in IFN treatment-naive patients with genotype 1 chronic hepatitis C
    Pianko, S.
    Yoshida, E.
    Zeuzem, S.
    Benhamou, Y.
    Bain, V.
    Pulkstenis, E.
    McHutchison, J. G.
    Subramanian, G. M.
    JOURNAL OF HEPATOLOGY, 2008, 48 : S306 - S307
  • [10] C-EDGE TN: Impact Of 12-Week Oral Regimen Of Grazoprevir (GZR, MK-5172)/Elbasvir (EBR, MK-8742) On Patient-Reported Outcomes (PROs) In Treatment-Naive Patients With Chronic Hepatitis C Virus (HCV) Genotype (GT) 1, 4, Or 6 Infection
    Arduino, Jean Marie
    Wang, Yang
    Brown, Deborah D.
    Khawaja, Shazia
    Martinez, Elisa
    Butterton, Joan R.
    Robertson, Michael
    Nwankwo, Chizoba
    Mast, T. Christopher
    HEPATOLOGY, 2015, 62 : 565A - 566A
1234